{"analyses":[{"ciLowerLimit":"0.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","estimateComment":"Reference level = RT + cisplatin","groupDescription":"Arms were compared using a one-sided log-rank test at the 0.025 significance level.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.32","paramType":"Hazard Ratio (HR)","paramValue":"0.95","statisticalComment":"One-sided log-rank significance level of 0.025","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.7","upperLimit":"77.1","value":"72.9"},{"groupId":"OG001","lowerLimit":"71.7","upperLimit":"79.9","value":"75.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"447"},{"groupId":"OG001","value":"444"}],"units":"Participants"}],"description":"Overall survival is defined as time from randomization to date of death from any cause. Patients last known to be alive are censored at the date of last contact. Three-year rates were estimated by the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin","id":"OG000","title":"RT + Cisplatin"},{"description":"Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin plus cetuximab","id":"OG001","title":"RT + Cisplatin + Cetuximab"}],"paramType":"NUMBER","populationDescription":"Randomized eligible patients with follow-up data","reportingStatus":"POSTED","timeFrame":"From randomization until 434 failures have occurred, approximately 5 years from start of study. (Patients are followed until death or study termination, whichever occurs first.)","title":"Overall Survival (OS) (3-year Rate Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}